THE CLINICAL syndrome of “myxedema heart” consists of an enlarged sluggish heart with low electrical voltages and flattened or inverted T waves on the electrocardiogram, changes which are reversible with the administration of thyroid hormone. Other abnormalities of the cardiovascular system, including bradycardia, diminished cardiac output, increased circulation time, and increased arteriovenous difference, may occur in myxedematous patients without overt involvement of the heart. The exact nature of the cardiac lesion in myxedema heart disease has been the subject of considerable debate (11, 15, 16). Some authors have believed that involvement of the myocardium by the myxedematous process is the dominant abnormality (1, 4, 14). The importance of coronary artery disease in myxedema has been both stressed (1, 4, 5) and questioned (2). Others have considered pericardial effusion the dominant feature of the disease (17); indeed, Kern et al. thought this effusion “a constant, early, and major factor” in the s...